Inflammation in ischemic stroke: Mechanisms, consequences and possible drug targets

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 8, 2014, Pages 1378-1396

  Ahmad, Muzamil ^a,b   Dar, Nawab J ^a,b   Bhat, Zubair S ^a,b   Hussain, Aehtesham ^a,b   Shah, Ayatullah ^a,b   Liu, Hao ^c,d   Graham, Steven H ^c,d  

^a CSIR INDIAN INSTITUTE OF INTEGRATIVE MEDICINE   (India)

^b ACADEMY OF SCIENTIFIC AND INNOVATIVE RESEARCH ACSIR   (India)

^c VA Pittsburgh Healthcare System   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cerebral ischemia; Cyclooxygenase 2; Cytokines and chemokines; Inflammation; Microglia; Middle cerebral artery occlusion; Prostaglandin

Indexed keywords

20 HYDROXYICOSATETRAENOIC ACID; ALPHA CHEMOKINE; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONIC ACID; CELL ADHESION MOLECULE; CHEMOKINE; CX3C CHEMOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ICOSATETRAENOIC ACID; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; L SELECTIN; MATRIX METALLOPROTEINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; NEUTROPHIL INHIBITORY FACTOR; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PADGEM PROTEIN; PROSTAGLANDIN SYNTHASE; SELECTIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; CYTOKINE;

APOPTOSIS; ARTICLE; ASTROCYTE; BRAIN ISCHEMIA; CELL ACTIVATION; CELL COMMUNICATION; CELL INFILTRATION; HUMAN; INFLAMMATION; MACROPHAGE; MICROGLIA; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OXIDATIVE STRESS; POST ISCHEMIC INFLAMMATION; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; ANIMAL; COMPLICATION; ENCEPHALITIS; GENE EXPRESSION REGULATION; METABOLISM; PHYSIOLOGY; STROKE;

ANIMALS; APOPTOSIS; BRAIN ISCHEMIA; CYTOKINES; ENCEPHALITIS; GENE EXPRESSION REGULATION; HUMANS; OXIDATIVE STRESS; STROKE;

EID: 84925763425     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527313666141023094720     Document Type: Article

References (364)

1. Yamashita K, Vogel P, Fritze K, et al.Monitoring the temporal and spatial activation pattern of astrocytes in focal cerebral ischemia using in situ hybridization to GFAP mRNA: comparison with sgp-2 and hsp70 mRNA and the effect of glutamate receptor antagonists. Brain Res 1996; 735(2): 285-97.
2. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet 2008; 371(9624): 1612-23.
3. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci 1999; 22(9): 391-7.
4. Phan TG, Wright PM, Markus R, et al.Salvaging the ischaemic penumbra: more than just reperfusion? Clin Exp Pharmacol Physiol 2002; 29(1-2): 1-10.
5. Chavez JC, Hurko O, Barone FC, Feuerstein GZ. Pharmacologic interventions for stroke: looking beyond the thrombolysis time window into the penumbra with biomarkers, not a stopwatch. Stroke 2009; 40(10): e558-63.
6. Barone FC. Ischemic stroke intervention requires mixed cellular protection of the penumbra. Curr Opin Investig Drugs 2009; 10(3): 220-3.
7. del Zoppo GJ, Poeck K, Pessin MS, et al.Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992; 32(1): 78-86.
8. Clark WM, Wissman S, Albers GW, et al.Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999; 282(21): 2019-26.
9. Furlan AJ, Katzan IL, Caplan LR. Thrombolytic Therapy in Acute Ischemic Stroke. Curr Treat Options Cardiovasc Med 2003; 5(3): 171-80.
10. Wardlaw JM, Murray V, Berge E, et al.Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 2012; 379(9834): 2364-72.
11. Barone FC, Feuerstein GZ. Inflammatory mediators and stroke: new opportunities for novel therapeutics. J Cereb Blood Flow Metab 1999; 19(8): 819-34.
12. Samson Y, Lapergue B, Hosseini H. Inflammation and ischaemic stroke: current status and future perspectives. Rev Neurol (Paris) 2005; 161(12 Pt 1): 1177-82.
13. Chamorro A, Hallenbeck J. The harms and benefits of inflammatory and immune responses in vascular disease. Stroke 2006; 37(2): 291-3.
14. Muir KW, Tyrrell P, Sattar N, Warburton E. Inflammation and ischaemic stroke. Curr Opin Neurol 2007; 20(3): 334-42.
15. Morioka T, Kalehua AN, Streit WJ. Characterization of microglial reaction after middle cerebral artery occlusion in rat brain. J Comp Neurol 1993; 327(1): 123-32.
16. Hallenbeck JM. Significance of the inflammatory response in brain ischemia. Acta Neurochir Suppl 1996; 66: 27-31.
17. Becker KJ. Inflammation and acute stroke. Curr Opin Neurol 1998; 11(1): 45-9.
18. Davies CA, Loddick SA, Stroemer RP, Hunt J, Rothwell NJ. An integrated analysis of the progression of cell responses induced by permanent focal middle cerebral artery occlusion in the rat. Exp Neurol 1998; 154(1): 199-212.
19. Zheng Z, Yenari MA. Post-ischemic inflammation: molecular mechanisms and therapeutic implications. Neurol Res 2004; 26(8): 884-92.
20. Lakhan SE, Kirchgessner A, Hofer M. Inflammatory mechanisms in ischemic stroke: therapeutic approaches. J Transl Med 2009; 7: 97.
21. Siesjo BK. Pathophysiology and treatment of focal cerebral ischemia. Part II: Mechanisms of damage and treatment. J Neurosurg 1992; 77(3): 337-54.
22. Chen H, Yoshioka H, Kim GS, et al.Oxidative stress in ischemic brain damage: mechanisms of cell death and potential molecular targets for neuroprotection. Antioxid Redox Signal 2011; 14(8): 1505-17.
23. Streit WJ. Microglia as neuroprotective, immunocompetent cells of the CNS. Glia 2002; 40(2): 133-9.
24. Danton GH, Dietrich WD. Inflammatory mechanisms after ischemia and stroke. J Neuropathol Exp Neurol 2003; 62(2): 127-36.
25. Siesjo BK, Siesjo P. Mechanisms of secondary brain injury. Eur J Anaesthesiol 1996; 13(3): 247-68.
26. Rosenberg GA. Ischemic brain edema. Prog Cardiovasc Dis 1999; 42(3): 209-16.
27. Han HS, Yenari MA. Cellular targets of brain inflammation in stroke. Curr Opin Investig Drugs 2003; 4(5): 522-9.
28. del Zoppo GJ. Acute anti-inflammatory approaches to ischemic stroke. Ann NY Acad Sci 2010; 1207: 143-8.
29. Wang X. Investigational anti-inflammatory agents for the treatment of ischaemic brain injury. Expert Opin Investig Drugs 2005; 14(4): 393-409.
30. Tuttolomondo A, Di Sciacca R, Di Raimondo D, et al.Inflammation as a therapeutic target in acute ischemic stroke treatment. Curr Top Med Chem 2009; 9(14): 1240-60.
31. Iadecola C, Anrather J. The immunology of stroke: from mechanisms to translation. Nat Med 2011; 17(7): 796-808.
32. Di Napoli M, Shah IM. Neuroinflammation and cerebrovascular disease in old age: a translational medicine perspective. J Aging Res 2011; 2011: 857484.
33. Ahmad M, Graham SH. Inflammation After Stroke: Mechanisms and Therapeutic Approaches. Transl Stroke Res 2010; 1(2): 74-84.
34. Patel AR, Ritzel R, McCullough LD, Liu F. Microglia and ischemic stroke: a double-edged sword. Int J Physiol Pathophysiol Pharmacol 2013; 5(2): 73-90.
35. Weinstein JR, Koerner IP, Moller T. Microglia in ischemic brain injury. Future Neurol 2010; 5(2): 227-46.
36. Dirnagl U. Bench to bedside: the quest for quality in experimental stroke research. J Cereb Blood Flow Metab 2006; 26(12): 1465-78.
37. Perez de la Ossa N, Davalos A. Neuroprotection in cerebral infarction: the opportunity of new studies. Cerebrovasc Dis 2007; 24 Suppl 1: 153-6.
38. Zaleska MM, Mercado ML, Chavez J, et al.The development of stroke therapeutics: promising mechanisms and translational challenges. Neuropharmacology 2009; 56(2): 329-41.
39. Sutherland BA, Minnerup J, Balami JS, et al.Neuroprotection for ischaemic stroke: translation from the bench to the bedside. Int J Stroke 2012; 7(5): 407-18.
40. Denes A, Thornton P, Rothwell NJ, Allan SM. Inflammation and brain injury: Acute cerebral ischaemia, peripheral and central inflammation. Brain Behav Immun 2009; 24(5): 708-23.
41. Emsley HC, Smith CJ, Gavin CM, et al.An early and sustained peripheral inflammatory response in acute ischaemic stroke: relationships with infection and atherosclerosis. J Neuroimmunol 2003; 139(1-2): 93-101.
42. Pozzilli C, Lenzi GL, Argentino C, et al.Peripheral white blood cell count in cerebral ischemic infarction. Acta Neurol Scand 1985; 71(5): 396-400.
43. Iadecola C, Alexander M. Cerebral ischemia and inflammation. Curr Opin Neurol 2001; 14(1): 89-94.
44. Buck BH, Liebeskind DS, Saver JL, et al.Early neutrophilia is associated with volume of ischemic tissue in acute stroke. Stroke 2008; 39(2): 355-60.
45. Akopov SE, Grigorian GS, Ovanessian GA. Deactivation of NO by polymorphonuclear leukocytes in patients with ischemic cerebral infarction. Stroke 1996; 27(12): 2337-8.
46. Price CJ, Wang D, Menon DK, et al.Intrinsic activated microglia map to the peri-infarct zone in the subacute phase of ischemic stroke. Stroke 2006; 37(7): 1749-53.
47. Breckwoldt MO, Chen JW, Stangenberg L, et al.Tracking the inflammatory response in stroke in vivo by sensing the enzyme myeloperoxidase. Proc Natl Acad Sci USA 2008; 105(47): 18584-9.
48. Connolly ES Jr, Winfree CJ, Springer TA, et al.Cerebral protection in homozygous null ICAM-1 mice after middle cerebral artery occlusion. Role of neutrophil adhesion in the pathogenesis of stroke. J Clin Invest 1996; 97(1): 209-16.
49. Garcia JH, Liu KF, Yoshida Y, et al.Influx of leukocytes and platelets in an evolving brain infarct (Wistar rat). Am J Pathol 1994; 144(1): 188-99.
50. Lerouet D, Beray-Berthat V, Palmier B, Plotkine M, Margaill I. Changes in oxidative stress, iNOS activity and neutrophil infiltration in severe transient focal cerebral ischemia in rats. Brain Res 2002; 958(1): 166-75.
51. Jiang N, Chopp M, Chahwala S. Neutrophil inhibitory factor treatment of focal cerebral ischemia in the rat. Brain Res 1998; 788(1-2): 25-34.
52. Harris AK, Ergul A, Kozak A, et al.Effect of neutrophil depletion on gelatinase expression, edema formation and hemorrhagic transformation after focal ischemic stroke. BMC Neurosci 2005; 6: 49.
53. Beray-Berthat V, Palmier B, Plotkine M, Margaill I. Neutrophils do not contribute to infarction, oxidative stress, and NO synthase activity in severe brain ischemia. Exp Neurol 2003; 182(2): 446-54.
54. Yilmaz G, Arumugam TV, Stokes KY, Granger DN. Role of T lymphocytes and interferon-gamma in ischemic stroke. Circulation 2006; 113(17): 2105-12.
55. Jiang N, Moyle M, Soule HR, Rote WE, Chopp M. Neutrophil inhibitory factor is neuroprotective after focal ischemia in rats. Ann Neurol 1995; 38(6): 935-42.
56. Mackay KB, Bailey SJ, King PD, et al.Neuroprotective effect of recombinant neutrophil inhibitory factor in transient focal cerebral ischaemia in the rat. Neurodegeneration 1996; 5(4): 319-23.
57. Krams M, Lees KR, Hacke W, et al.Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279, 276 in acute ischemic stroke. Stroke 2003; 34(11): 2543-8.
58. Matsuo Y, Onodera H, Shiga Y, et al.Correlation between myeloperoxidase-quantified neutrophil accumulation and ischemic brain injury in the rat. Effects of neutrophil depletion. Stroke 1994; 25(7): 1469-75.
59. Hartl R, Schurer L, Schmid-Schonbein GW, del Zoppo GJ. Experimental antileukocyte interventions in cerebral ischemia. J Cereb Blood Flow Metab 1996; 16(6): 1108-19.
60. Hayward NJ, Elliott PJ, Sawyer SD, Bronson RT, Bartus RT. Lack of evidence for neutrophil participation during infarct formation following focal cerebral ischemia in the rat. Exp Neurol 1996; 139(2): 188-202.
61. Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 2007; 10(11): 1387-94.
62. Biber K, Neumann H, Inoue K, Boddeke HW. Neuronal 'On' and 'Off' signals control microglia. Trends Neurosci 2007; 30(11): 596-602.
63. Davalos D, Grutzendler J, Yang G, et al.ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci 2005; 8(6): 752-8.
64. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005; 308(5726): 1314-8.
65. Jin R, Yang G, Li G. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J Leukoc Biol 2010; 87(5): 779-89.
66. Nakajima K, Kohsaka S. Microglia: activation and their significance in the central nervous system. J Biochem 2001; 130(2): 169-75.
67. Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 2007; 10(11): 1387-94.
68. Melchior B, Puntambekar SS, Carson MJ. Microglia and the control of autoreactive T cell responses. Neurochem Int 2006; 49(2): 145-53.
69. Banati RB, Gehrmann J, Fau-Schubert P, et al. Cytotoxicity of microglia. Glia 1993; 7(1): 111-8.
70. Banati RB, Gehrmann J, Schubert P, Kreutzberg GW. Cytotoxicity of microglia. Glia 1993; 7(1): 111-8.
71. Zhang F, White JG, Iadecola C. Nitric oxide donors increase blood flow and reduce brain damage in focal ischemia: evidence that nitric oxide is beneficial in the early stages of cerebral ischemia. J Cereb Blood Flow Metab 1994; 14(2): 217-26.
72. Rothwell N, Allan S, Toulmond S. The role of interleukin 1 in acute neurodegeneration and stroke: pathophysiological and therapeutic implications. J Clin Invest 1997; 100(11): 2648-52.
73. Pappata S, Levasseur M, Gunn RN, et al.Thalamic microglial activation in ischemic stroke detected in vivo by PET and 11C]PK1195. Neurology 2000; 55(7): 1052-4.
74. Beschorner R, Schluesener HJ, Gozalan F, Meyermann R, Schwab JM. Infiltrating CD14+ monocytes and expression of CD14 by activated parenchymal microglia/macrophages contribute to the pool of CD14+ cells in ischemic brain lesions. J Neuroimmunol 2002; 126(1-2): 107-15.
75. Lampl Y, Boaz M, Gilad R, et al.Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 2007; 69(14): 1404-10.
76. Mabuchi T, Kitagawa K, Ohtsuki T, et al.Contribution of microglia/macrophages to expansion of infarction and response of oligodendrocytes after focal cerebral ischemia in rats. Stroke 2000; 31(7): 1735-43.
77. Rupalla K, Allegrini PR, Sauer D, Wiessner C. Time course of microglia activation and apoptosis in various brain regions after permanent focal cerebral ischemia in mice. Acta Neuropathol 1998; 96(2): 172-8.
78. Jander S, Schroeter M, D'Urso D, et al.Focal ischaemia of the rat brain elicits an unusual inflammatory response: early appearance of CD8+ macrophages/microglia. Eur J Neurosci 1998; 10(2): 680-8.
79. Iadecola C, Forster C, Nogawa S, Clark HB, Ross ME. Cyclooxygenase-2 immunoreactivity in the human brain following cerebral ischemia. Acta Neuropathol 1999; 98(1): 9-14.
80. Morioka T, Kalehua AN, Streit WJ. The microglial reaction in the rat dorsal hippocampus following transient forebrain ischemia. J Cereb Blood Flow Metab 1991; 11(6): 966-73.
81. Schwartz M, Butovsky O, Bruck W, Hanisch UK. Microglial phenotype: is the commitment reversible? Trends Neurosci 2006; 29(2): 68-74.
82. Colton CA. Heterogeneity of microglial activation in the innate immune response in the brain. J Neuroimmune Pharmacol 2009; 4(4): 399-418.
83. Lalancette-Hebert M, Gowing G, Simard A, Weng YC, Kriz J. Selective ablation of proliferating microglial cells exacerbates ischemic injury in the brain. J Neurosci 2007; 27(10): 2596-605.
84. Fukumoto K, Takagi N, Yamamoto R, et al.Prostanoid EP1 receptor antagonist reduces blood-brain barrier leakage after cerebral ischemia. Eur J Pharmacol 2010; 640(1-3): 82-6.
85. Barreto G, White RE, Ouyang Y, Xu L, Giffard RG. Astrocytes: targets for neuroprotection in stroke. Cent Nerv Syst Agents Med Chem 2011; 11(2): 164-73.
86. Akram A, Gibson CL, Grubb BD. Neuroprotection mediated by the EP(4) receptor avoids the detrimental side effects of COX-2 inhibitors following ischaemic injury. Neuropharmacology 2013; 65: 165-72.
87. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006; 7(1): 41-53.
88. Dong Y, Benveniste EN. Immune function of astrocytes. Glia 2001; 36(2): 180-90.
89. Bertsch T, Casarin W, Kretschmar M, et al.Protein S-100B: a serum marker for ischemic and infectious injury of cerebral tissue. Clin Chem Lab Med 2001; 39(4): 319-23.
90. Fischmann A, Gloor M, Fasler S, et al.Muscular involvement assessed by MRI correlates to motor function measurement values in oculopharyngeal muscular dystrophy. J Neurol 2011; 258(7): 1333-40.
91. Krupinski J, Kaluza J, Kumar P, Kumar S. Immunocytochemical studies of cellular reaction in human ischemic brain stroke. MAB anti-CD68 stains macrophages, astrocytes and microglial cells in infarcted area. Folia Neuropathol 1996; 34(1): 17-24.
92. Kawamoto Y, Akiguchi I, Tomimoto H, et al.Upregulated expression of 14-3-3 proteins in astrocytes from human cerebrovascular ischemic lesions. Stroke 2006; 37(3): 830-5.
93. Niebroj-Dobosz I, Rafalowska J, Lukasiuk M, Pfeffer A, Mossakowski MJ. Immunochemical analysis of some proteins in cerebrospinal fluid and serum of patients with ischemic strokes. Folia Neuropathol 1994; 32(3): 129-37.
94. Foerch C, Niessner M, Back T, et al.Diagnostic accuracy of plasma glial fibrillary acidic protein for differentiating intracerebral hemorrhage and cerebral ischemia in patients with symptoms of acute stroke. Clin Chem 2012; 58(1): 237-45.
95. Petito CK, Halaby IA. Relationship between ischemia and ischemic neuronal necrosis to astrocyte expression of glial fibrillary acidic protein. Int J Dev Neurosci 1993; 11(2): 239-47.
96. Kato H, Takahashi A, Itoyama Y. Cell cycle protein expression in proliferating microglia and astrocytes following transient global cerebral ischemia in the rat. Brain Res Bull 2003; 60(3): 215-21.
97. Kadhim HJ, Duchateau J, Sebire G. Cytokines and brain injury: invited review. J Intensive Care Med 2008; 23(4): 236-49.
98. Nowicka D, Rogozinska K, Aleksy M, Witte OW, Skangiel-Kramska J. Spatiotemporal dynamics of astroglial and microglial responses after photothrombotic stroke in the rat brain. Acta Neurobiol Exp (Wars) 2008; 68(2): 155-68.
99. Endoh M, Maiese K, Wagner J. Expression of the inducible form of nitric oxide synthase by reactive astrocytes after transient global ischemia. Brain Res 1994; 651(1-2): 92-100.
100. Hewett SJ, Muir JK, Lobner D, Symons A, Choi DW. Potentiation of oxygen-glucose deprivation-induced neuronal death after induction of iNOS. Stroke 1996; 27(9): 1586-91.
101. Schubert P, Morino T, Miyazaki H, et al.Cascading glia reactions: a common pathomechanism and its differentiated control by cyclic nucleotide signaling. Ann NY Acad Sci 2000; 903: 24-33.
102. Cotrina ML, Lin JH, Nedergaard M. Cytoskeletal assembly and ATP release regulate astrocytic calcium signaling. J Neurosci 1998; 18(21): 8794-804.
103. Asano T, Mori T, Shimoda T, et al.Arundic acid (ONO-2506) ameliorates delayed ischemic brain damage by preventing astrocytic overproduction of S100B. Curr Drug Targets CNS Neurol Disord 2005; 4(2): 127-42.
104. Tateishi N, Mori T, Kagamiishi Y, et al.Astrocytic activation and delayed infarct expansion after permanent focal ischemia in rats. Part II: suppression of astrocytic activation by a novel agent (R)-(- )-2-propyloctanoic acid (ONO-2506) leads to mitigation of delayed infarct expansion and early improvement of neurologic deficits. J Cereb Blood Flow Metab 2002; 22(6): 723-34.
105. Fang SH, Wei EQ, Zhou Y, et al.Increased expression of cysteinyl leukotriene receptor-1 in the brain mediates neuronal damage and astrogliosis after focal cerebral ischemia in rats. Neuroscience 2006; 140(3): 969-79.
106. Zhao CZ, Zhao B, Zhang XY, et al.Cysteinyl leukotriene receptor 2 is spatiotemporally involved in neuron injury, astrocytosis and microgliosis after focal cerebral ischemia in rats. Neuroscience 2011; 189: 1-11.
107. Zhao Y, Rempe DA. Targeting astrocytes for stroke therapy. Neurotherapeutics 2010; 7(4): 439-51.
108. Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007; 8(1): 57-69.
109. Vincent VA, Tilders FJ, Van Dam AM. Inhibition of endotoxininduced nitric oxide synthase production in microglial cells by the presence of astroglial cells: a role for transforming growth factor beta. Glia 1997; 19(3): 190-8.
110. Min KJ, Yang MS, Kim SU, Jou I, Joe EH. Astrocytes induce hemeoxygenase-1 expression in microglia: a feasible mechanism for preventing excessive brain inflammation. J Neurosci 2006; 26(6): 1880-7.
111. Chothia C, Jones EY. The molecular structure of cell adhesion molecules. Annu Rev Biochem 1997; 66: 823-62.
112. Togashi H, Sakisaka T, Takai Y. Cell adhesion molecules in the central nervous system. Cell Adh Migr 2009; 3(1).
113. Albelda SM, Smith CW, Ward PA. Adhesion molecules and inflammatory injury. FASEB J 1994; 8(8): 504-12.
114. Frijns CJ, Kappelle LJ. Inflammatory cell adhesion molecules in ischemic cerebrovascular disease. Stroke 2002; 33(8): 2115-22.
115. Kim JS. Cytokines and adhesion molecules in stroke and related diseases. J Neurol Sci 1996; 137(2): 69-78.
116. Rodriguez-Yanez M, Castillo J. Role of inflammatory markers in brain ischemia. Curr Opin Neurol 2008; 21(3): 353-7.
117. Sughrue ME, Mehra A, Connolly ES Jr, D'Ambrosio AL. Antiadhesion molecule strategies as potential neuroprotective agents in cerebral ischemia: a critical review of the literature. Inflamm Res 2004; 53(10): 497-508.
118. Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cell Signal 2001; 13(2): 85-94.
119. Wang X, Feuerstein GZ. Induced expression of adhesion molecules following focal brain ischemia. J Neurotrauma 1995; 12(5): 825-32.
120. Winquist RJ, Kerr S. Cerebral ischemia-reperfusion injury and adhesion. Neurology 1997; 49(5 Suppl 4): S23-6.
121. Pantoni L, Sarti C, Inzitari D. Cytokines and cell adhesion molecules in cerebral ischemia: experimental bases and therapeutic perspectives. Arterioscler Thromb Vasc Biol 1998; 18(4): 503-13.
122. Yilmaz G, Granger DN. Cell adhesion molecules and ischemic stroke. Neurol Res 2008; 30(8): 783-93.
123. Ruehl ML, Orozco JA, Stoker MB, et al.Protective effects of inhibiting both blood and vascular selectins after stroke and reperfusion. Neurol Res 2002; 24(3): 226-32.
124. Wei YS, Lan Y, Huang RY, et al.Association of the singlenucleotide polymorphism and haplotype of the P-selectin gene with ischemic stroke. J Thromb Thrombolysis 2009; 27(1): 75-81.
125. Wei YS, Lan Y, Meng LQ, Nong LG. The association of L-selectin polymorphisms with L-selectin serum levels and risk of ischemic stroke. J Thromb Thrombolysis 2011; 32(1): 110-5.
126. Roy S, Das S, Danaboina R, et al.Association of E-selectin Gene Polymorphism (S128R) with Ischemic Stroke and Stroke Subtypes. Inflammation 2014; 37(2): 599-603.
127. Wang HC, Lin WC, Yang TM, et al. The association between symptomatic delayed cerebral infarction and serum adhesion molecules in aneurysmal subarachnoid hemorrhage. Neurosurgery 2011; 68(6): 1611-7.
128. Kozuka K, Kohriyama T, Nomura E, et al.Endothelial markers and adhesion molecules in acute ischemic stroke--sequential change and differences in stroke subtype. Atherosclerosis 2002; 161(1): 161-8.
129. Cherian P, Hankey GJ, Eikelboom JW, et al.Endothelial and platelet activation in acute ischemic stroke and its etiological subtypes. Stroke 2003; 34(9): 2132-7.
130. Love S, Barber R. Expression of P-selectin and intercellular adhesion molecule-1 in human brain after focal infarction or cardiac arrest. Neuropathol Appl Neurobiol 2001; 27(6): 465-73.
131. Fassbender K, Mossner R, Motsch L, et al.Circulating selectinand immunoglobulin-type adhesion molecules in acute ischemic stroke. Stroke 1995; 26(8): 1361-4.
132. Nissen JJ, Mantle D, Blackburn A, et al.The selectin superfamily: the role of selectin adhesion molecules in delayed cerebral ischaemia after aneurysmal subarachnoid haemorrhage. Acta Neurochir Suppl 2000; 76: 55-60.
133. Nissen JJ, Mantle D, Gregson B, Mendelow AD. Serum concentration of adhesion molecules in patients with delayed ischaemic neurological deficit after aneurysmal subarachnoid haemorrhage: the immunoglobulin and selectin superfamilies. J Neurol Neurosurg Psychiatry 2001; 71(3): 329-33.
134. Yenari MA, Sun GH, Kunis DM, Onley D, Vexler V. L-selectin inhibition does not reduce injury in a rabbit model of transient focal cerebral ischemia. Neurol Res 2001; 23(1): 72-8.
135. Huang J, Kim LJ, Mealey R, et al.Neuronal protection in stroke by an sLex-glycosylated complement inhibitory protein. Science 1999; 285(5427): 595-9.
136. Huang J, Choudhri TF, Winfree CJ, et al.Postischemic cerebrovascular E-selectin expression mediates tissue injury in murine stroke. Stroke 2000; 31(12): 3047-53.
137. Suzuki H, Abe K, Tojo S, et al.Expressions of P-selectin- and HSP72-like immunoreactivities in rat brain after transient middle cerebral artery occlusion. Brain Res 1997; 759(2): 321-9.
138. Suzuki H, Abe K, Tojo S, et al.A change of P-selectin immunoreactivity in rat brain after transient and permanent middle cerebral artery occlusion. Neurol Res 1998; 20(5): 463-9.
139. Suzuki H, Abe K, Tojo S, et al.Postischemic expression of Pselectin immunoreactivity in rat brain. Neurosci Lett 1997; 228(3): 151-4.
140. Connolly ES Jr, Winfree CJ, Prestigiacomo CJ, et al.Exacerbation of cerebral injury in mice that express the P-selectin gene: identification of P-selectin blockade as a new target for the treatment of stroke. Circ Res 1997; 81(3): 304-10.
141. Kisucka J, Chauhan AK, Zhao BQ, et al.Elevated levels of soluble P-selectin in mice alter blood-brain barrier function, exacerbate stroke, and promote atherosclerosis. Blood 2009; 113(23): 6015-22.
142. Jin AY, Tuor UI, Rushforth D, et al.Reduced blood brain barrier breakdown in P-selectin deficient mice following transient ischemic stroke: a future therapeutic target for treatment of stroke. BMC Neurosci 2010; 11: 12.
143. Suzuki H, Abe K, Tojo SJ, et al.Reduction of ischemic brain injury by anti-P-selectin monoclonal antibody after permanent middle cerebral artery occlusion in rat. Neurol Res 1999; 21(3): 269-76.
144. Ma XJ, Cheng JW, Zhang J, et al.E-selectin deficiency attenuates brain ischemia in mice. CNS Neurosci Ther 2012; 18(11): 903-8.
145. Soriano SG, Wang YF, Wagner DD, Frenette PS. P- and Eselectin- deficient mice are susceptible to cerebral ischemiareperfusion injury. Brain Res 1999; 835(2): 360-4.
146. Shyu KG, Chang H, Lin CC. Serum levels of intercellular adhesion molecule-1 and E-selectin in patients with acute ischaemic stroke. J Neurol 1997; 244(2): 90-3.
147. Bitsch A, Klene W, Murtada L, Prange H, Rieckmann P. A longitudinal prospective study of soluble adhesion molecules in acute stroke. Stroke 1998; 29(10): 2129-35.
148. Simundic AM, Basic V, Topic E, et al.Soluble adhesion molecules in acute ischemic stroke. Clin Invest Med 2004; 27(2): 86-92.
149. Selakovic V, Colic M, Jovanovic M, Raicevic R, Jovicic A. Cerebrospinal fluid and plasma concentration of soluble intercellular adhesion molecule 1, vascular cell adhesion molecule 1 and endothelial leukocyte adhesion molecule in patients with acute ischemic brain disease. Vojnosanit Pregl 2003; 60(2): 139-46.
150. Blann A, Kumar P, Krupinski J, et al.Soluble intercelluar adhesion molecule-1, E-selectin, vascular cell adhesion molecule-1 and von Willebrand factor in stroke. Blood Coagul Fibrinolysis 1999; 10(5): 277-84.
151. Blum A, Khazim K, Merei M, et al.The stroke trial - can we predict clinical outcome of patients with ischemic stroke by measuring soluble cell adhesion molecules (CAM)? Eur Cytokine Netw 2006; 17(4): 295-8.
152. Chamorro A, Cervera A, Castillo J, et al.Unfractionated heparin is associated with a lower rise of serum vascular cell adhesion molecule-1 in acute ischemic stroke patients. Neurosci Lett 2002; 328(3): 229-32.
153. Campbell DJ, Woodward M, Chalmers JP, et al.Soluble vascular cell adhesion molecule 1 and N-terminal pro-B-type natriuretic peptide in predicting ischemic stroke in patients with cerebrovascular disease. Arch Neurol 2006; 63(1): 60-5.
154. Krupinski J, Kaluza J, Kumar P, Kumar S, Wang JM. Role of angiogenesis in patients with cerebral ischemic stroke. Stroke 1994; 25(9): 1794-8.
155. Hoyte LC, Brooks KJ, Nagel S, et al.Molecular magnetic resonance imaging of acute vascular cell adhesion molecule-1 expression in a mouse model of cerebral ischemia. J Cereb Blood Flow Metab 2010; 30(6): 1178-87.
156. Cervera A, Justicia C, Reverter JC, Planas AM, Chamorro A. Steady plasma concentration of unfractionated heparin reduces infarct volume and prevents inflammatory damage after transient focal cerebral ischemia in the rat. J Neurosci Res 2004; 77(4): 565-72.
157. Berti R, Williams AJ, Moffett JR, et al.Quantitative real-time RTPCR analysis of inflammatory gene expression associated with ischemia-reperfusion brain injury. J Cereb Blood Flow Metab 2002; 22(9): 1068-79.
158. Justicia C, Martin A, Rojas S, et al.Anti-VCAM-1 antibodies did not protect against ischemic damage either in rats or in mice. J Cereb Blood Flow Metab 2006; 26(3): 421-32.
159. Matsuo Y, Onodera H, Shiga Y, et al.Role of cell adhesion molecules in brain injury after transient middle cerebral artery occlusion in the rat. Brain Res 1994; 656(2): 344-52.
160. Wang X, Siren AL, Liu Y, et al.Upregulation of intercellular adhesion molecule 1 (ICAM-1) on brain microvascular endothelial cells in rat ischemic cortex. Brain Res Mol Brain Res 1994; 26(1- 2): 61-8.
161. Zhang RL, Chopp M, Zaloga C, et al.The temporal profiles of ICAM-1 protein and mRNA expression after transient MCA occlusion in the rat. Brain Res 1995; 682(1-2): 182-8.
162. Kitagawa K, Matsumoto M, Mabuchi T, et al.Deficiency of intercellular adhesion molecule 1 attenuates microcirculatory disturbance and infarction size in focal cerebral ischemia. J Cereb Blood Flow Metab 1998; 18(12): 1336-45.
163. Soriano SG, Lipton SA, Wang YF, et al.Intercellular adhesion molecule-1-deficient mice are less susceptible to cerebral ischemiareperfusion injury. Ann Neurol 1996; 39(5): 618-24.
164. Kitagawa K, Matsumoto M, Ohtsuki T, et al.Deficiency of intercellular adhesion molecule 1 fails to mitigate selective neuronal death after transient global ischemia. Brain Res 1999; 847(2): 166-74.
165. Bowes MP, Zivin JA, Rothlein R. Monoclonal antibody to the ICAM-1 adhesion site reduces neurological damage in a rabbit cerebral embolism stroke model. Exp Neurol 1993; 119(2): 215-9.
166. Kanemoto Y, Nakase H, Akita N, Sakaki T. Effects of antiintercellular adhesion molecule-1 antibody on reperfusion injury induced by late reperfusion in the rat middle cerebral artery occlusion model. Neurosurgery 2002; 51(4): 1034-41.
167. Chopp M, Li Y, Jiang N, Zhang RL, Prostak J. Antibodies against adhesion molecules reduce apoptosis after transient middle cerebral artery occlusion in rat brain. J Cereb Blood Flow Metab 1996; 16(4): 578-84.
168. Vemuganti R, Dempsey RJ, Bowen KK. Inhibition of intercellular adhesion molecule-1 protein expression by antisense oligonucleotides is neuroprotective after transient middle cerebral artery occlusion in rat. Stroke 2004; 35(1): 179-84.
169. Mayanagi K, Katakam PV, Gaspar T, Domoki F, Busija DW. Acute treatment with rosuvastatin protects insulin resistant (C57BL/6J ob/ob) mice against transient cerebral ischemia. J Cereb Blood Flow Metab 2008; 28(12): 1927-35.
170. Bajetto A, Bonavia R, Barbero S, Florio T, Schettini G. Chemokines and their receptors in the central nervous system. Front Neuroendocrinol 2001; 22(3): 147-84.
171. Losy J, Zaremba J. Monocyte chemoattractant protein-1 is increased in the cerebrospinal fluid of patients with ischemic stroke. Stroke 2001; 32(11): 2695-6.
172. Yan YP, Sailor KA, Lang BT, et al.Monocyte chemoattractant protein-1 plays a critical role in neuroblast migration after focal cerebral ischemia. J Cereb Blood Flow Metab 2007; 27(6): 1213-24.
173. Sanchez-Moreno C, Dashe JF, Scott T, et al.Decreased levels of plasma vitamin C and increased concentrations of inflammatory and oxidative stress markers after stroke. Stroke 2004; 35(1): 163-8.
174. Garlichs CD, Kozina S, Fateh-Moghadam S, et al.Upregulation of CD40-CD40 ligand (CD154) in patients with acute cerebral ischemia. Stroke 2003; 34(6): 1412-8.
175. Buraczynska K, Luchowski P, Wojczal J, Ksiazek A, Stelmasiak Z. Monocyte chemoattractant protein (MCP-1) A-2518G gene polymorphism in stroke patients with different comorbidities. Clin Biochem 2010; 43(18): 1421-6.
176. Losy J, Zaremba J, Skrobanski P. CXCL1 (GRO-alpha) chemokine in acute ischaemic stroke patients. Folia Neuropathol 2005; 43(2): 97-102.
177. Ormstad H, Aass HC, Lund-Sorensen N, Amthor KF, Sandvik L. Serum levels of cytokines and C-reactive protein in acute ischemic stroke patients, and their relationship to stroke lateralization, type, and infarct volume. J Neurol 2011; 258(4): 677-85.
178. Kostulas N, Kivisakk P, Huang Y, et al.Ischemic stroke is associated with a systemic increase of blood mononuclear cells expressing interleukin-8 mRNA. Stroke 1998; 29(2): 462-6.
179. Tarkowski E, Rosengren L, Blomstrand C, et al.Intrathecal release of pro- and anti-inflammatory cytokines during stroke. Clin Exp Immunol 1997; 110(3): 492-9.
180. Bates S, Read SJ, Harrison DC, et al.Characterisation of gene expression changes following permanent MCAO in the rat using subtractive hybridisation. Brain Res Mol Brain Res 2001; 93(1): 70-80.
181. Che X, Ye W, Panga L, Wu DC, Yang GY. Monocyte chemoattractant protein-1 expressed in neurons and astrocytes during focal ischemia in mice. Brain Res 2001; 902(2): 171-7.
182. Gourmala NG, Buttini M, Limonta S, Sauter A, Boddeke HW. Differential and time-dependent expression of monocyte chemoattractant protein-1 mRNA by astrocytes and macrophages in rat brain: effects of ischemia and peripheral lipopolysaccharide administration. J Neuroimmunol 1997; 74(1-2): 35-44.
183. Hughes PM, Allegrini PR, Rudin M, et al.Monocyte chemoattractant protein-1 deficiency is protective in a murine stroke model. J Cereb Blood Flow Metab 2002; 22(3): 308-17.
184. Strecker JK, Minnerup J, Schutte-Nutgen K, et al.Monocyte chemoattractant protein-1-deficiency results in altered blood-brain barrier breakdown after experimental stroke. Stroke 2013; 44(9): 2536-44.
185. Chen Y, Hallenbeck JM, Ruetzler C, et al.Overexpression of monocyte chemoattractant protein 1 in the brain exacerbates ischemic brain injury and is associated with recruitment of inflammatory cells. J Cereb Blood Flow Metab 2003; 23(6): 748-55.
186. Stamatovic SM, Shakui P, Keep RF, et al.Monocyte chemoattractant protein-1 regulation of blood-brain barrier permeability. J Cereb Blood Flow Metab 2005; 25(5): 593-606.
187. Kumai Y, Ooboshi H, Takada J, et al.Anti-monocyte chemoattractant protein-1 gene therapy protects against focal brain ischemia in hypertensive rats. J Cereb Blood Flow Metab 2004; 24(12): 1359-68.
188. Bazan JF, Bacon KB, Hardiman G, et al.A new class of membrane-bound chemokine with a CX3C motif. Nature 1997; 385(6617): 640-4.
189. Pan Y, Lloyd C, Zhou H, et al.Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature 1997; 387(6633): 611-7.
190. Chapman GA, Moores K, Harrison D, et al.Fractalkine cleavage from neuronal membranes represents an acute event in the inflammatory response to excitotoxic brain damage. J Neurosci 2000; 20(15): RC87.
191. Imai T, Hieshima K, Haskell C, et al.Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997; 91(4): 521-30.
192. Combadiere C, Salzwedel K, Smith ED, et al.Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1. J Biol Chem 1998; 273(37): 23799-804.
193. Harrison JK, Jiang Y, Chen S, et al.Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. Proc Natl Acad Sci USA 1998; 95(18): 10896-901.
194. Maciejewski-Lenoir D, Chen S, Feng L, Maki R, Bacon KB. Characterization of fractalkine in rat brain cells: migratory and activation signals for CX3CR-1-expressing microglia. J Immunol 1999; 163(3): 1628-35.
195. Nishiyori A, Minami M, Ohtani Y, et al.Localization of fractalkine and CX3CR1 mRNAs in rat brain: does fractalkine play a role in signaling from neuron to microglia? FEBS Lett 1998; 429(2): 167-72.
196. Lavergne E, Labreuche J, Daoudi M, et al.Adverse associations between CX3CR1 polymorphisms and risk of cardiovascular or cerebrovascular disease. Arterioscler Thromb Vasc Biol 2005; 25(4): 847-53.
197. Li Z, Luo S, Wang F, et al.An association study between polymorphisms of the fractalkine receptor gene, CX3CR1, and cerebral infarction in the Han Chinese population. J Neurol Sci 2012; 320(1-2): 12-5.
198. Donohue MM, Cain K, Zierath D, et al.Higher plasma fractalkine is associated with better 6-month outcome from ischemic stroke. Stroke 2012; 43(9): 2300-6.
199. Tarozzo G, Campanella M, Ghiani M, Bulfone A, Beltramo M. Expression of fractalkine and its receptor, CX3CR1, in response to ischaemia-reperfusion brain injury in the rat. Eur J Neurosci 2002; 15(10): 1663-8.
200. Cipriani R, Villa P, Chece G, et al.CX3CL1 is neuroprotective in permanent focal cerebral ischemia in rodents. J Neurosci 2011; 31(45): 16327-35.
201. Soriano SG, Amaravadi LS, Wang YF, et al.Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury. J Neuroimmunol 2002; 125(1-2): 59-65.
202. Tang Z, Gan Y, Liu Q, et al.CX3CR1 deficiency suppresses activation and neurotoxicity of microglia/macrophage in experimental ischemic stroke. J Neuroinflammation 2014; 11(1): 26.
203. Denes A, Ferenczi S, Halasz J, Kornyei Z, Kovacs KJ. Role of CX3CR1 (fractalkine receptor) in brain damage and inflammation induced by focal cerebral ischemia in mouse. J Cereb Blood Flow Metab 2008; 28(10): 1707-21.
204. Zhu J, Zhou Z, Liu Y, Zheng J. Fractalkine and CX3CR1 are involved in the migration of intravenously grafted human bone marrow stromal cells toward ischemic brain lesion in rats. Brain Res 2009; 1287: 173-83.
205. Adibhatla RM, Dempsy R, Hatcher JF. Integration of cytokine biology and lipid metabolism in stroke. Front Biosci 2008; 13: 1250-70.
206. Perini F, Morra M, Alecci M, et al.Temporal profile of serum antiinflammatory and pro-inflammatory interleukins in acute ischemic stroke patients. Neurol Sci 2001; 22(4): 289-96.
207. Vila N, Castillo J, Davalos A, Chamorro A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke 2000; 31(10): 2325-9.
208. Iadecola C, Zhang F, Casey R, Nagayama M, Ross ME. Delayed reduction of ischemic brain injury and neurological deficits in mice lacking the inducible nitric oxide synthase gene. J Neurosci 1997; 17(23): 9157-64.
209. Orion D, Schwammenthal Y, Reshef T, et al.Interleukin-6 and soluble intercellular adhesion molecule-1 in acute brain ischaemia. Eur J Neurol 2008; 15(4): 323-8.
210. Emsley HC, Smith CJ, Georgiu RF, et al.Interleukin-6 and acute ischaemic stroke. Acta Neurol Scand 2005; 112(4): 273-4.
211. Basic Kes V, Simundic AM, Nikolac N, Topic E, Demarin V. Proinflammatory and anti-inflammatory cytokines in acute ischemic stroke and their relation to early neurological deficit and stroke outcome. Clin Biochem 2008; 41(16-17): 1330-4.
212. Nagayama M, Aber T, Nagayama T, Ross ME, Iadecola C. Agedependent increase in ischemic brain injury in wild-type mice and in mice lacking the inducible nitric oxide synthase gene. J Cereb Blood Flow Metab 1999; 19(6): 661-6.
213. Smith CJ, Emsley HC, Gavin CM, et al. Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol 2004; 4: 2.
214. Waje-Andreassen U, Krakenes J, Ulvestad E, et al.IL-6: an early marker for outcome in acute ischemic stroke. Acta Neurol Scand 2005; 111(6): 360-5.
215. Tarkowski E, Rosengren L, Blomstrand C, et al.Early intrathecal production of interleukin-6 predicts the size of brain lesion in stroke. Stroke 1995; 26(8): 1393-8.
216. Sun Y, Lu CJ, Lin CH, Wen LL. Interleukin-1beta is increased in the cerebrospinal fluid of patients with small infarcts. Eur J Neurol 2009; 16(7): 858-63.
217. Fassbender K, Rossol S, Kammer T, et al.Proinflammatory cytokines in serum of patients with acute cerebral ischemia: kinetics of secretion and relation to the extent of brain damage and outcome of disease. J Neurol Sci 1994; 122(2): 135-9.
218. Zaremba J, Skrobanski P, Losy J. Tumour necrosis factor-alpha is increased in the cerebrospinal fluid and serum of ischaemic stroke patients and correlates with the volume of evolving brain infarct. Biomed Pharmacother 2001; 55(5): 258-63.
219. Intiso D, Zarrelli MM, Lagioia G, et al.Tumor necrosis factor alpha serum levels and inflammatory response in acute ischemic stroke patients. Neurol Sci 2004; 24(6): 390-6.
220. Buttini M, Sauter A, Boddeke HW. Induction of interleukin-1 beta mRNA after focal cerebral ischaemia in the rat. Brain Res Mol Brain Res 1994; 23(1-2): 126-34.
221. Minami M, Kuraishi Y, Yabuuchi K, Yamazaki A, Satoh M. Induction of interleukin-1 beta mRNA in rat brain after transient forebrain ischemia. J Neurochem 1992; 58(1): 390-2.
222. Yabuuchi K, Minami M, Katsumata S, Yamazaki A, Satoh M. An in situ hybridization study on interleukin-1 beta mRNA induced by transient forebrain ischemia in the rat brain. Brain Res Mol Brain Res 1994; 26(1-2): 135-42.
223. Haqqani AS, Nesic M, Preston E, et al.Characterization of vascular protein expression patterns in cerebral ischemia/reperfusion using laser capture microdissection and ICAT-nanoLC-MS/MS. FASEB J 2005; 19(13): 1809-21.
224. Yamasaki Y, Matsuura N, Shozuhara H, et al.Interleukin-1 as a pathogenetic mediator of ischemic brain damage in rats. Stroke 1995; 26(4): 676-80.
225. Loddick SA, Rothwell NJ. Neuroprotective effects of human recombinant interleukin-1 receptor antagonist in focal cerebral ischaemia in the rat. J Cereb Blood Flow Metab 1996; 16(5): 932-40.
226. Boutin H, LeFeuvre RA, Horai R, et al.Role of IL-1alpha and IL- 1beta in ischemic brain damage. J Neurosci 2001; 21(15): 5528-34.
227. Shaftel SS, Carlson TJ, Olschowka JA, et al.Chronic interleukin- 1beta expression in mouse brain leads to leukocyte infiltration and neutrophil-independent blood brain barrier permeability without overt neurodegeneration. J Neurosci 2007; 27(35): 9301-9.
228. Rothwell NJ, Luheshi GN. Interleukin 1 in the brain: biology, pathology and therapeutic target. Trends Neurosci 2000; 23(12): 618-25.
229. Basu A, Lazovic J, Krady JK, et al.Interleukin-1 and the interleukin-1 type 1 receptor are essential for the progressive neurodegeneration that ensues subsequent to a mild hypoxic/ischemic injury. J Cereb Blood Flow Metab 2005; 25(1): 17-29.
230. Lazovic J, Basu A, Lin HW, et al.Neuroinflammation and both cytotoxic and vasogenic edema are reduced in interleukin-1 type 1 receptor-deficient mice conferring neuroprotection. Stroke 2005; 36(10): 2226-31.
231. Yang GY, Zhao YJ, Davidson BL, Betz AL. Overexpression of interleukin-1 receptor antagonist in the mouse brain reduces ischemic brain injury. Brain Res 1997; 751(2): 181-8.
232. Mulcahy NJ, Ross J, Rothwell NJ, Loddick SA. Delayed administration of interleukin-1 receptor antagonist protects against transient cerebral ischaemia in the rat. Br J Pharmacol 2003; 140(3): 471-6.
233. Touzani O, Boutin H, LeFeuvre R, et al.Interleukin-1 influences ischemic brain damage in the mouse independently of the interleukin-1 type I receptor. J Neurosci 2002; 22(1): 38-43.
234. Schielke GP, Yang GY, Shivers BD, Betz AL. Reduced ischemic brain injury in interleukin-1 beta converting enzyme-deficient mice. J Cereb Blood Flow Metab 1998; 18(2): 180-5.
235. Relton JK, Martin D, Thompson RC, Russell DA. Peripheral administration of Interleukin-1 Receptor antagonist inhibits brain damage after focal cerebral ischemia in the rat. Exp Neurol 1996; 138(2): 206-13.
236. Stroemer RP, Rothwell NJ. Cortical protection by localized striatal injection of IL-1ra following cerebral ischemia in the rat. J Cereb Blood Flow Metab 1997; 17(6): 597-604.
237. Seripa D, Dobrina A, Margaglione M, et al.Relevance of interleukin-1 receptor antagonist intron-2 polymorphism in ischemic stroke. Cerebrovasc Dis 2003; 15(4): 276-81.
238. Rezaii AA, Hoseinipanah SM, Hajilooi M, et al.Interleukin-1 receptor antagonist gene polymorphism and susceptibility to ischemic stroke. Immunol Invest 2009; 38(3-4): 220-30.
239. Worrall BB, Brott TG, Brown RD, Jr., et al.IL1RN VNTR polymorphism in ischemic stroke: analysis in 3 populations. Stroke 2007; 38(4): 1189-96.
240. Emsley HC, Smith CJ, Georgiou RF, et al.A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry 2005; 76(10): 1366-72.
241. Rubattu S, Speranza R, Ferrari M, et al.A role of TNF-alpha gene variant on juvenile ischemic stroke: a case-control study. Eur J Neurol 2005; 12(12): 989-93.
242. Zaremba J, Losy J. Early TNF-alpha levels correlate with ischaemic stroke severity. Acta Neurol Scand 2001; 104(5): 288-95.
243. Dziewulska D, Mossakowski MJ. Cellular expression of tumor necrosis factor a and its receptors in human ischemic stroke. Clin Neuropathol 2003; 22(1): 35-40.
244. Hallenbeck JM. The many faces of tumor necrosis factor in stroke. Nat Med 2002; 8(12): 1363-8.
245. Botchkina GI, Geimonen E, Bilof ML, Villarreal O, Tracey KJ. Loss of NF-kappaB activity during cerebral ischemia and TNF cytotoxicity. Mol Med 1999; 5(6): 372-81.
246. Park KP, Rosell A, Foerch C, et al.Plasma and brain matrix metalloproteinase-9 after acute focal cerebral ischemia in rats. Stroke 2009; 40(8): 2836-42.
247. Buttini M, Appel K, Sauter A, Gebicke-Haerter PJ, Boddeke HW. Expression of tumor necrosis factor alpha after focal cerebral ischaemia in the rat. Neuroscience 1996; 71(1): 1-16.
248. Uno H, Matsuyama T, Akita H, Nishimura H, Sugita M. Induction of tumor necrosis factor-alpha in the mouse hippocampus following transient forebrain ischemia. J Cereb Blood Flow Metab 1997; 17(5): 491-9.
249. Pettigrew LC, Kindy MS, Scheff S, et al.Focal cerebral ischemia in the TNFalpha-transgenic rat. J Neuroinflammation 2008; 5: 47.
250. Yang GY, Gong C, Qin Z, et al.Inhibition of TNFalpha attenuates infarct volume and ICAM-1 expression in ischemic mouse brain. Neuroreport 1998; 9(9): 2131-4.
251. Nawashiro H, Martin D, Hallenbeck JM. Neuroprotective effects of TNF binding protein in focal cerebral ischemia. Brain Res 1997; 778(2): 265-71.
252. Murakami Y, Saito K, Hara A, et al.Increases in tumor necrosis factor-alpha following transient global cerebral ischemia do not contribute to neuron death in mouse hippocampus. J Neurochem 2005; 93(6): 1616-22.
253. Nawashiro H, Tasaki K, Ruetzler CA, Hallenbeck JM. TNF-alpha pretreatment induces protective effects against focal cerebral ischemia in mice. J Cereb Blood Flow Metab 1997; 17(5): 483-90.
254. Pradillo JM, Romera C, Hurtado O, et al.TNFR1 upregulation mediates tolerance after brain ischemic preconditioning. J Cereb Blood Flow Metab 2005; 25(2): 193-203.
255. Caso JR, Lizasoain I, Lorenzo P, Moro MA, Leza JC. The role of tumor necrosis factor-alpha in stress-induced worsening of cerebral ischemia in rats. Neuroscience 2006; 142(1): 59-69.
256. Yin L, Ohtaki H, Nakamachi T, et al.Delayed expressed TNFR1 co-localize with ICAM-1 in astrocyte in mice brain after transient focal ischemia. Neurosci Lett 2004; 370(1): 30-5.
257. Bruce AJ, Boling W, Kindy MS, et al.Altered neuronal and microglial responses to excitotoxic and ischemic brain injury in mice lacking TNF receptors. Nat Med 1996; 2(7): 788-94.
258. Iadecola C, Zhang F. Nitric oxide-dependent and -independent components of cerebrovasodilation elicited by hypercapnia. Am J Physiol 1994; 266(2 Pt 2): R546-52.
259. Dalkara T, Moskowitz MA. Neurotoxic and neuroprotective roles of nitric oxide in cerebral ischaemia. Int Rev Neurobiol 1997; 40: 319-36.
260. Llorens S, Jordan J, Nava E. The nitric oxide pathway in the cardiovascular system. J Physiol Biochem 2002; 58(3): 179-88.
261. Jordan J, Segura T, Brea D, Galindo MF, Castillo J. Inflammation as therapeutic objective in stroke. Curr Pharm Des 2008; 14(33): 3549-64.
262. Cui J, Holmes EH, Greene TG, Liu PK. Oxidative DNA damage precedes DNA fragmentation after experimental stroke in rat brain. FASEB J 2000; 14(7): 955-67.
263. Ito Y, Ohkubo T, Asano Y, et al.Nitric oxide production during cerebral ischemia and reperfusion in eNOS- and nNOS-knockout mice. Curr Neurovasc Res 2010; 7(1): 23-31.
264. Adachi N, Lei B, Soutani M, Arai T. Different roles of neuronal and endothelial nitric oxide synthases on ischemic nitric oxide production in gerbil striatum. Neurosci Lett 2000; 288(2): 151-4.
265. Liu K, Li Q, Zhang L, Zheng X. The dynamic detection of NO during stroke and reperfusion in vivo. Brain Inj 2009; 23(5): 450-8.
266. Wei G, Dawson VL, Zweier JL. Role of neuronal and endothelial nitric oxide synthase in nitric oxide generation in the brain following cerebral ischemia. Biochim Biophys Acta 1999; 1455(1): 23-34.
267. Iadecola C, Zhang F, Xu S, Casey R, Ross ME. Inducible nitric oxide synthase gene expression in brain following cerebral ischemia. J Cereb Blood Flow Metab 1995; 15(3): 378-84.
268. Parmentier S, Bohme GA, Lerouet D, et al.Selective inhibition of inducible nitric oxide synthase prevents ischaemic brain injury. Br J Pharmacol 1999; 127(2): 546-52.
269. Forster C, Clark HB, Ross ME, Iadecola C. Inducible nitric oxide synthase expression in human cerebral infarcts. Acta Neuropathol 1999; 97(3): 215-20.
270. Askalan R, Deveber G, Ho M, Ma J, Hawkins C. Astrocyticinducible nitric oxide synthase in the ischemic developing human brain. Pediatr Res 2006; 60(6): 687-92.
271. Iadecola C, Zhang F, Xu X. Inhibition of inducible nitric oxide synthase ameliorates cerebral ischemic damage. Am J Physiol 1995; 268(1 Pt 2): R286-92.
272. Parmentier-Batteur S, Bohme GA, Lerouet D, et al.Antisense oligodeoxynucleotide to inducible nitric oxide synthase protects against transient focal cerebral ischemia-induced brain injury. J Cereb Blood Flow Metab 2001; 21(1): 15-21.
273. Pruss H, Prass K, Ghaeni L, et al.Inducible nitric oxide synthase does not mediate brain damage after transient focal cerebral ischemia in mice. J Cereb Blood Flow Metab 2008; 28(3): 526-39.
274. Liu R, Zhang L, Lan X, et al.Protection by borneol on cortical neurons against oxygen-glucose deprivation/reperfusion: involvement of anti-oxidation and anti-inflammation through nuclear transcription factor kappaappaB signaling pathway. Neuroscience 2011; 176: 408-19.
275. Martin-de-Saavedra MD, del Barrio L, Canas N, et al.Chondroitin sulfate reduces cell death of rat hippocampal slices subjected to oxygen and glucose deprivation by inhibiting p38, NFkappaB and iNOS. Neurochem Int 2011; 58(6): 676-83.
276. Liu RL, Xiong QJ, Shu Q, et al.Hyperoside protects cortical neurons from oxygen-glucose deprivation-reperfusion induced injury via nitric oxide signal pathway. Brain Res 2012; 1469: 164-73.
277. Asahi M, Asahi K, Jung JC, et al.Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab 2000; 20(12): 1681-9.
278. Jiang X, Namura S, Nagata I. Matrix metalloproteinase inhibitor KB-R7785 attenuates brain damage resulting from permanent focal cerebral ischemia in mice. Neurosci Lett 2001; 305(1): 41-4.
279. del Zoppo GJ, Milner R, Mabuchi T, et al.Microglial activation and matrix protease generation during focal cerebral ischemia. Stroke 2007; 38(2 Suppl): 646-51.
280. Planas AM, Sole S, Justicia C. Expression and activation of matrix metalloproteinase-2 and -9 in rat brain after transient focal cerebral ischemia. Neurobiol Dis 2001; 8(5): 834-46.
281. Fujimura M, Gasche Y, Morita-Fujimura Y, et al.Early appearance of activated matrix metalloproteinase-9 and blood-brain barrier disruption in mice after focal cerebral ischemia and reperfusion. Brain Res 1999; 842(1): 92-100.
282. Amantea D, Nappi G, Bernardi G, Bagetta G, Corasaniti MT. Postischemic brain damage: pathophysiology and role of inflammatory mediators. FEBS J 2009; 276(1): 13-26.
283. del Zoppo GJ. Inflammation and the neurovascular unit in the setting of focal cerebral ischemia. Neuroscience 2009; 158(3): 972-82.
284. Lee YM, Chang SY, Jung SO, Kweon HS, Lee JS. Cloning and expression of alpha class glutathione S-transferase gene from the small hermaphroditic fish Rivulus marmoratus (Cyprinodontiformes, Rivulidae). Mar Pollut Bull 2005; 51(8-12): 776-83.
285. Justicia C, Panes J, Sole S, et al.Neutrophil infiltration increases matrix metalloproteinase-9 in the ischemic brain after occlusion/reperfusion of the middle cerebral artery in rats. J Cereb Blood Flow Metab 2003; 23(12): 1430-40.
286. Cui J, Chen S, Zhang C, et al.Inhibition of MMP-9 by a selective gelatinase inhibitor protects neurovasculature from embolic focal cerebral ischemia. Mol Neurodegener 2012; 7: 21.
287. Gasche Y, Copin JC, Sugawara T, Fujimura M, Chan PH. Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. J Cereb Blood Flow Metab 2001; 21(12): 1393-400.
288. Svedin P, Hagberg H, Savman K, Zhu C, Mallard C. Matrix metalloproteinase-9 gene knock-out protects the immature brain after cerebral hypoxia-ischemia. J Neurosci 2007; 27(7): 1511-8.
289. Asahi M, Sumii T, Fini ME, Itohara S, Lo EH. Matrix metalloproteinase 2 gene knockout has no effect on acute brain injury after focal ischemia. Neuroreport 2001; 12(13): 3003-7.
290. Reilly MP, Lawson JA, FitzGerald GA. Eicosanoids and isoeicosanoids: indices of cellular function and oxidant stress. J Nutr 1998; 128(2 Suppl): 434S-8S.
291. Kaufmann WE, Worley PF, Pegg J, Bremer M, Isakson P. COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci USA 1996; 93(6): 2317-21.
292. Yamagata K, Andreasson KI, Kaufmann WE, Barnes CA, Worley PF. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 1993; 11(2): 371-86.
293. Miettinen S, Fusco FR, Yrjanheikki J, et al.Spreading depression and focal brain ischemia induce cyclooxygenase-2 in cortical neurons through N-methyl-D-aspartic acid-receptors and phospholipase A2. Proc Natl Acad Sci USA 1997; 94(12): 6500-5.
294. Sairanen T, Ristimaki A, Karjalainen-Lindsberg ML, et al.Cyclooxygenase-2 is induced globally in infarcted human brain. Ann Neurol 1998; 43(6): 738-47.
295. Ferronato S, Lira MG, Olivato S, et al.Upregulated expression of Toll-like receptor 4 in peripheral blood of ischaemic stroke patients correlates with cyclooxygenase 2 expression. Eur J Vasc Endovasc Surg 2011; 41(3): 358-63.
296. Ahmad M, Zhang Y, Liu H, Rose ME, Graham SH. Prolonged opportunity for neuroprotection in experimental stroke with selective blockade of cyclooxygenase-2 activity. Brain Res 2009; 1279: 168-73.
297. Candelario-Jalil E, Gonzalez-Falcon A, Garcia-Cabrera M, Leon OS, Fiebich BL. Wide therapeutic time window for nimesulide neuroprotection in a model of transient focal cerebral ischemia in the rat. Brain Res 2004; 1007(1-2): 98-108.
298. Minghetti L. Role of COX-2 in inflammatory and degenerative brain diseases. Subcell Biochem 2007; 42: 127-41.
299. del Zoppo G, Ginis I, Hallenbeck JM, et al.Inflammation and stroke: putative role for cytokines, adhesion molecules and iNOS in brain response to ischemia. Brain Pathol 2000; 10(1): 95-112.
300. Candelario-Jalil E, Fiebich BL. Cyclooxygenase inhibition in ischemic brain injury. Curr Pharm Des 2008; 14(14): 1401-18.
301. Iadecola C, Niwa K, Nogawa S, et al.Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc Natl Acad Sci USA 2001; 98(3): 1294-9.
302. Dore S, Otsuka T, Mito T, et al.Neuronal overexpression of cyclooxygenase-2 increases cerebral infarction. Ann Neurol 2003; 54(2): 155-62.
303. Nakayama M, Uchimura K, Zhu RL, et al.Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia. Proc Natl Acad Sci USA 1998; 95(18): 10954-9.
304. Nogawa S, Zhang F, Ross ME, Iadecola C. Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci 1997; 17(8): 2746-55.
305. Schwab JM, Nguyen TD, Postler E, Meyermann R, Schluesener HJ. Selective accumulation of cyclooxygenase-1-expressing microglial cells/macrophages in lesions of human focal cerebral ischemia. Acta Neuropathol 2000; 99(6): 609-14.
306. Iadecola C, Sugimoto K, Niwa K, Kazama K, Ross ME. Increased susceptibility to ischemic brain injury in cyclooxygenase-1- deficient mice. J Cereb Blood Flow Metab 2001; 21(12): 1436-41.
307. Lin H, Lin TN, Cheung WM, et al.Cyclooxygenase-1 and bicistronic cyclooxygenase-1/prostacyclin synthase gene transfer protect against ischemic cerebral infarction. Circulation 2002; 105(16): 1962-9.
308. Candelario-Jalil E, Gonzalez-Falcon A, Garcia-Cabrera M, et al.Assessment of the relative contribution of COX-1 and COX-2 isoforms to ischemia-induced oxidative damage and neurodegeneration following transient global cerebral ischemia. J Neurochem 2003; 86(3): 545-55.
309. Cheung RT, Pei Z, Feng ZH, Zou LY. Cyclooxygenase-1 gene knockout does not alter middle cerebral artery occlusion in a mouse stroke model. Neurosci Lett 2002; 330(1): 57-60.
310. Gaudet RJ, Levine L. Effect of unilateral common carotid artery occlusion on levels of prostaglandins D2, F2 alpha and 6-ketoprostaglandin F1 alpha in gerbil brain. Stroke 1980; 11(6): 648-52.
311. Masuda Y, Ochi Y, Ochi Y, Kadokawa T. A possible role of endogenously formed cerebral prostaglandins in the development of adaptive protection against cerebral hypoxia/ischemia in mice. Methods Find Exp Clin Pharmacol 1987; 9(11): 721-7.
312. Huttemeier PC, Kamiyama Y, Su M, Watkins WD, Benveniste H. Microdialysis measurements of PGD2, TXB2 and 6-KETO-PGF1 alpha in rat CA1 hippocampus during transient cerebral ischemia. Prostaglandins 1993; 45(2): 177-87.
313. Narumiya S. Prostanoids in immunity: roles revealed by mice deficient in their receptors. Life Sci 2003; 74(2-3): 391-5.
314. Matsuoka T, Narumiya S. Prostaglandin receptor signaling in disease. Sci World J 2007; 7: 1329-47.
315. Mohan S, Ahmad AS, Glushakov AV, Chambers C, Dore S. Putative role of prostaglandin receptor in intracerebral hemorrhage. Front Neurol 2012; 3: 145.
316. Andreasson K. Emerging roles of PGE2 receptors in models of neurological disease. Prostaglandins Other Lipid Mediat 2010; 91(3-4): 104-12.
317. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999; 79(4): 1193-226.
318. Namba T, Sugimoto Y, Negishi M, et al.Alternative splicing of Cterminal tail of prostaglandin E receptor subtype EP3 determines G-protein specificity. Nature 1993; 365(6442): 166-70.
319. Ahmad AS, Saleem S, Ahmad M, Dore S. Prostaglandin EP1 receptor contributes to excitotoxicity and focal ischemic brain damage. Toxicol Sci 2006; 89(1): 265-70.
320. Kawano T, Anrather J, Zhou P, et al.Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat Med 2006; 12(2): 225-9.
321. Abe T, Kunz A, Shimamura M, et al.The neuroprotective effect of prostaglandin E2 EP1 receptor inhibition has a wide therapeutic window, is sustained in time and is not sexually dimorphic. J Cereb Blood Flow Metab 2009; 29(1): 66-72.
322. Zhou P, Qian L, Chou T, Iadecola C. Neuroprotection by PGE2 receptor EP1 inhibition involves the PTEN/AKT pathway. Neurobiol Dis 2008; 29(3): 543-51.
323. Saleem S, Li RC, Wei G, Dore S. Effects of EP1 receptor on cerebral blood flow in the middle cerebral artery occlusion model of stroke in mice. J Neurosci Res 2007; 85(11): 2433-40.
324. McCullough L, Wu L, Haughey N, et al.Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J Neurosci 2004; 24(1): 257-68.
325. Liu D, Wu L, Breyer R, Mattson MP, Andreasson K. Neuroprotection by the PGE2 EP2 receptor in permanent focal cerebral ischemia. Ann Neurol 2005; 57(5): 758-61.
326. Ahmad AS, Zhuang H, Echeverria V, Dore S. Stimulation of prostaglandin EP2 receptors prevents NMDA-induced excitotoxicity. J Neurotrauma 2006; 23(12): 1895-903.
327. Ahmad M, Ahmad AS, Zhuang H, et al.Stimulation of prostaglandin E2-EP3 receptors exacerbates stroke and excitotoxic injury. J Neuroimmunol 2007; 184(1-2): 172-9.
328. Saleem S, Kim YT, Maruyama T, Narumiya S, Dore S. Reduced acute brain injury in PGE2 EP3 receptor-deficient mice after cerebral ischemia. J Neuroimmunol 2009; 208(1-2): 87-93.
329. Li J, Liang X, Wang Q, et al.Misoprostol, an anti-ulcer agent and PGE2 receptor agonist, protects against cerebral ischemia. Neurosci Lett 2008; 438(2): 210-5.
330. Ahmad AS, Ahmad M, de Brum-Fernandes AJ, Dore S. Prostaglandin EP4 receptor agonist protects against acute neurotoxicity. Brain Res 2005; 1066(1-2): 71-7.
331. Saleem S, Zhuang H, de Brum-Fernandes AJ, et al.PGD(2) DP1 receptor protects brain from ischemia-reperfusion injury. Eur J Neurosci 2007; 26(1): 73-8.
332. Ahmad AS, Ahmad M, Maruyama T, Narumiya S, Doré S. Prostaglandin D2 DP1 receptor is beneficial in ischemic stroke and in acute exicitotoxicity in young and old mice. Age 2010; 32(3): 271-82.
333. Liang X, Wu L, Hand T, Andreasson K. Prostaglandin D2 mediates neuronal protection via the DP1 receptor. J Neurochem 2005; 92(3): 477-86.
334. Taniguchi H, Mohri I, Okabe-Arahori H, et al.Prostaglandin D2 protects neonatal mouse brain from hypoxic ischemic injury. J Neurosci 2007; 27(16): 4303-12.
335. Pereira MP, Hurtado O, Cardenas A, et al.Rosiglitazone and 15- deoxy-Delta12, 14-prostaglandin J2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms. J Cereb Blood Flow Metab 2006; 26(2): 218-29.
336. Ou Z, Zhao X, Labiche LA, et al.Neuronal expression of peroxisome proliferator-activated receptor-gamma (PPARgamma) and 15d-prostaglandin J2--mediated protection of brain after experimental cerebral ischemia in rat. Brain Res 2006; 1096(1): 196-203.
337. Zhao X, Zhang Y, Strong R, Grotta JC, Aronowski J. 15d- Prostaglandin J2 activates peroxisome proliferator-activated receptor-gamma, promotes expression of catalase, and reduces inflammation, behavioral dysfunction, and neuronal loss after intracerebral hemorrhage in rats. J Cereb Blood Flow Metab 2006; 26(6): 811-20.
338. Liu H, Li W, Ahmad M, et al.Modification of ubiquitin-C-terminal hydrolase-L1 by cyclopentenone prostaglandins exacerbates hypoxic injury. Neurobiol Dis 2011; 41(2): 318-28.
339. Liu H, Li W, Rose ME, et al.Prostaglandin D2 toxicity in primary neurons is mediated through its bioactive cyclopentenone metabolites. Neurotoxicology 2013; 39: 35-44.
340. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987; 237(4819): 1171-6.
341. Tomimoto H, Shibata M, Ihara M, et al.A comparative study on the expression of cyclooxygenase and 5-lipoxygenase during cerebral ischemia in humans. Acta Neuropathol 2002; 104(6): 601-7.
342. Minamisawa H, Terashi A, Katayama Y, et al.Brain eicosanoid levels in spontaneously hypertensive rats after ischemia with reperfusion: leukotriene C4 as a possible cause of cerebral edema. Stroke 1988; 19(3): 372-7.
343. Manev H, Uz T, Qu T. 5-Lipoxygenase and cyclooxygenase mRNA expression in rat hippocampus:early response to glutamate receptor activation by kainate. Exp Gerontol 2000; 35(9-10): 1201-9.
344. Hu M, Zhang X, Liu W, Cui H, Di N. Longitudinal changes of defensive and offensive factors in focal cerebral ischemiareperfusion in rats. Brain Res Bull 2009; 79(6): 371-5.
345. Ohtsuki T, Matsumoto M, Hayashi Y, et al.Reperfusion induces 5- lipoxygenase translocation and leukotriene C4 production in ischemic brain. Am J Physiol 1995; 268(3 Pt 2): H1249-57.
346. Baskaya MK, Hu Y, Donaldson D, et al.Protective effect of the 5- lipoxygenase inhibitor AA-861 on cerebral edema after transient ischemia. J Neurosurg 1996; 85(1): 112-6.
347. Song Y, Wei EQ, Zhang WP, et al.Minocycline protects PC12 cells from ischemic-like injury and inhibits 5-lipoxygenase activation. Neuroreport 2004; 15(14): 2181-4.
348. Kitagawa K, Matsumoto M, Hori M. Cerebral ischemia in 5- lipoxygenase knockout mice. Brain Res 2004; 1004(1-2): 198-202.
349. Ye XH, Wu Y, Guo PP, et al.Lipoxin A(4) analogue protects brain and reduces inflammation in a rat model of focal cerebral ischemia reperfusion. Brain Res 2010; 1323: 174-83.
350. Wu Y, Wang YP, Guo P, et al.A lipoxin A4 analog ameliorates blood-brain barrier dysfunction and reduces MMP-9 expression in a rat model of focal cerebral ischemia-reperfusion injury. J Mol Neurosci 2012; 46(3): 483-91.
351. Wu L, Miao S, Zou LB, et al.Lipoxin A4 inhibits 5-lipoxygenase translocation and leukotrienes biosynthesis to exert a neuroprotective effect in cerebral ischemia/reperfusion injury. J Mol Neurosci 2012; 48(1): 185-200.
352. Sobrado M, Pereira MP, Ballesteros I, et al.Synthesis of lipoxin A4 by 5-lipoxygenase mediates PPARgamma-dependent, neuroprotective effects of rosiglitazone in experimental stroke. J Neurosci 2009; 29(12): 3875-84.
353. van Leyen K, Kim HY, Lee SR, et al.Baicalein and 12/15- lipoxygenase in the ischemic brain. Stroke 2006; 37(12): 3014-8.
354. Chen J, Weinstein PR, Graham SH. Attenuation of postischemic brain hypoperfusion and reperfusion injury by the cyclooxygenaselipoxygenase inhibitor BW755C. J Neurosurg 1995; 83(1): 99-104.
355. Renic M, Klaus JA, Omura T, et al.Effect of 20-HETE inhibition on infarct volume and cerebral blood flow after transient middle cerebral artery occlusion. J Cereb Blood Flow Metab 2009; 29(3): 629-39.
356. Poloyac SM, Zhang Y, Bies RR, Kochanek PM, Graham SH. Protective effect of the 20-HETE inhibitor HET0016 on brain damage after temporary focal ischemia. J Cereb Blood Flow Metab 2006; 26(12): 1551-61.
357. Galvao RI, Diogenes JP, Maia GC, et al.Tenoxicam exerts a neuroprotective action after cerebral ischemia in rats. Neurochem Res 2005; 30(1): 39-46.
358. Gebremedhin D, Lange AR, Narayanan J, et al.Cat cerebral arterial smooth muscle cells express cytochrome P450 4A2 enzyme and produce the vasoconstrictor 20-HETE which enhances L-type Ca2+ current. J Physiol 1998; 507(Pt 3): 771-81.
359. Gebremedhin D, Lange AR, Lowry TF, et al.Production of 20- HETE and its role in autoregulation of cerebral blood flow. Circul Res 2000; 87(1): 60-5.
360. Ward NC, Croft KD, Blacker D, et al.Cytochrome P450 metabolites of arachidonic acid are elevated in stroke patients compared with healthy controls. Clin Sci 2011; 121(11): 501-7.
361. Omura T, Tanaka Y, Miyata N, et al.Effect of a new inhibitor of the synthesis of 20-HETE on cerebral ischemia reperfusion injury. Stroke 2006; 37(5): 1307-13.
362. Tanaka Y, Omura T, Fukasawa M, et al.Continuous inhibition of 20-HETE synthesis by TS-011 improves neurological and functional outcomes after transient focal cerebral ischemia in rats. Neurosci Res 2007; 59(4): 475-80.
363. Alkayed NJ, Narayanan J, Gebremedhin D, et al.Molecular characterization of an arachidonic acid epoxygenase in rat brain astrocytes. Stroke 1996; 27(5): 971-9.
364. Shaik JS, Ahmad M, Li W, et al.Soluble epoxide hydrolase inhibitor trans-4-4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]- benzoic acid is neuroprotective in rat model of ischemic stroke. Am J Physiol Heart Circ Physiol 2013; 305(11): H1605-13.